Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] Semaglutide and GLP-1 analogues as weight-loss agents

The increasing global frequency of obesity and its resultant health effects are well documented.1–4 Drug development for obesity has been hampered by concerns over cardiovascular safety and a paucity of significant efficacy.1 One possible pharmaceutical solution to promote weight loss lies in the glucagon-like peptide-1 (GLP-1) analogue class of drugs, one of which is semaglutide and is approved with a dosing schedule of once per a week for the treatment of type 2 diabetes.5 Reported in The Lancet, Patrick O’Neil and colleagues’ Article5 presents a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial of daily subcutaneous semaglutide (doses ranging from 0·05 mg to 0·4 mg) versus liraglutide (3·0 mg per day) and matched placebo for the treatment of non-diabetic obesity over a 52-week period.